ScholarIQanswers from OpenAlex & ORCID
Richard Furie
ResearcherPublications, citations & collaboration network
Richard Furie is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Richard Furie have?
ScholarIQindexed works
Richard Furie has 384 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Richard Furie have?
ScholarIQcitation count
Richard Furie has 25,714 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Richard Furie?
ScholarIQh-index
Richard Furie has an h-index of 72 in OpenAlex.
What is the i10-index of Richard Furie?
ScholarIQi10-index
Richard Furie has an i10-index of 172 in OpenAlex.
What is the ORCID of Richard Furie?
ScholarIQorcid
The ORCID for Richard Furie is on the source record.
What is the OpenAlex record for Richard Furie?
ScholarIQopenalex
The OpenAlex for Richard Furie is on the source record.
What are the most-cited papers on Richard Furie?
ScholarIQmost cited works
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
Richard Furie, Michelle Petri, Omid Zamani, Ricard Cervera, Daniel J. Wallace, Dana Tegzová, Jorge Sánchez‐Guerrero, Andreas Schwarting, Joan T. Merrill, Winn Chatham, William Stohl, Ellen M. Ginzler, Douglas R. Hough, Z. John Zhong, William W. Freimuth, Ronald van Vollenhoven, BLISS-76 Study Group
Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeks
Stanley Cohen, Paul Emery, Maria Greenwald, Maxime Dougados, Richard Furie, Mark C. Genovese, Edward Keystone, J. Loveless, Gerd‐Rüdiger Burmester, Matthew Cravets, E. Hessey, T Shaw, Mark C. Totoritis
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study
Brad H. Rovin, Richard Furie, Kevin Latinis, R. John Looney, Fernando C. Fervenza, Jorge Sánchez‐Guerrero, Romeo Maciuca, David Zhang, Jay Garg, Paul Brunetta, Gerald B. Appel, LUNAR Investigator Group
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
Eric F. Morand, Richard Furie, Yoshiya Tanaka, Ian N Bruce, Anca Askanase, Christophe Richez, Sang‐Cheol Bae, Philip Z. Brohawn, Lilia Pineda, Anna Berglind, Raj Tummala
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
Richard Furie, Brad H. Rovin, Frédéric Houssiau, Ana Malvar, Y K Onno Teng, Gabriel Contreras, Zahir Amoura, Xueqing Yu, Chi-Chiu Mok, Mittermayer B. Santiago, Amit Saxena, Yulia Green, Beulah Ji, C. Kleoudis, Susan W. Burriss, Carly Barnett, David A. Roth